Shanghai Pharmaceuticals Holding Co., Ltd. (02607) announced a proposed profit distribution for the first half of 2025, subject to shareholder approval. According to the unaudited report, the consolidated net profit attributable to shareholders amounted to RMB4,458,864,876.61. The proposed plan includes a cash dividend of RMB1.20 tax inclusive for every ten shares, based on the total share capital of 3,708,361,809 shares as of 30 June 2025. The overall cash dividend would reach RMB445,003,417.08, representing 9.98% of the net profit attributable to shareholders for the same period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments